Clinical Trial Search

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560

Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134

Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67

Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants

Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX — 2130 TEAEs

Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale

Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score

Primary: Number of Dose Limiting Toxicity Events — 0; 0 Dose Limiting Toxicity Events

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0 Participants

Primary: Change From Baseline in Activities of Daily Living (ADL) at 18 Months — -11.58; -13.45 units on a scale — p=0.82

Primary: Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo — 14; 21 Participants — p=<0.16

Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260

Primary: Treatment Emergent Adverse Events (TEAEs) — 21; 23 participants

Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…

Primary: Summary of Participants Reporting Treatment-Emergent Adverse Events For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600) — 60; 37; 21…

Primary: Apnea Hypopnea Index - Crossover — 34.9; 39.6 units on a scale

Primary: Changes in Intervention Response as Evaluated by the Clinical Global Impression of Change (CGIC) — 0; 0; 5; 2 Participants

Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)

Primary: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) — -13.72; -15.11; -14.38 score on a scale

Primary: Hamilton Rating Scale for Depression (24 Item) — 10.94 Units on a Scale

Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53

Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words

Primary: Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. — 0; 0; 0; 0 Participants

Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02

Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02

Primary: Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr) — -0.050; -0.122; -0.183; -0.255 standard uptake value…

Primary: F2-isoprostane Level Urine F2-Isoprostanes — 0.40; -2.02; 0.45 nanogram per miligram — p=0.83

Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522